Ventripoint Provides Corporate Update on Sales Initiatives
|
Toronto, Canada – June 8, 2017 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to provide a corporate update on its business activities.
Whole-Heart VMS The VMS is approved for the analysis of the right ventricle (RV) of the heart for anyone where the cardiologist deems the information is warranted or desired in the United States, Canada and Europe. The VMS-PLUS™ has recently been approved by Health Canada for the measurement of volumes of the other 3 chambers of the heart - right atrium (RA), left ventricle (LV) and left atrium (LA). “Ventripoint has achieved a “world first” with the approval of a whole-heart analysis system for 2D ultrasound exams, which provides accurate and reliable measurements equivalent to an MRI,” stated Dr. George Adams, CEO of Ventripoint. Sales and Marketing Now that the Company has “home-country” approval, it has been recruiting sales and marketing staff and interviewing potential distributors to assess different markets worldwide for their readiness for the VMS-PLUS. The recent focus has been on the Middle East and North Africa (MENA) region, where heart disease is particularly prevalent. For example; cardiovascular disease is responsible for one in five deaths in the United Arab Emirates (UAE) and one in four adults in Saudi Arabia are likely to have a heart attack within the next 10 years. The UAE has 70 public and private hospitals and 150 medical centres and clinics and is opening a new hospital every month. Saudi Arabia has approximately 600 hospitals and 2282 clinical centres and is expanding its healthcare system. The Company hired a representative for the region who attended the CSI Dubai 2017 cardiac conference in Dubai in April. He met with 70 cardiologists from the region and did calls at local hospitals to verify their readiness. The Company has also identified a regulatory consultant for the region, which has reciprocal arrangements between countries and requires a simple a registration of the VMS-PLUS in each country. Leading cardiac hospitals in the region have requested formal presentations to their cardiology groups so the Company will be returning to the region in July for this purpose, as well as to continue discussions with potential distributors and partners, and to begin the process to make formal regulatory submissions throughout the region in preparation for installations of the VMS-PLUS. The region is especially interesting as major imaging company recently signed a memorandum of understanding with the Ministry of Health for the U.A.E., whereby it will equip and service radiology departments in 11 hospitals in exchange for per patient service fees. This is the model the Company would like to deploy in the region and to our knowledge it is the first agreement using this model for imaging products. The Company has also identified and is interviewing several seasoned marketing people in Canada, Asia Pacific and the U.S.A.. It has commissioned a market survey in Canada to refine the positioning of the VMS-PLUS prior to beginning formal marketing efforts in September. Informal marketing efforts through the Company's clinical connections will continue throughout the summer. The Company has hired a new application specialist who will accompany sales staff on sales calls and train new users. She will begin in-depth training in Toronto this month, and will be available for the MENA launch in July. Annual General Meeting and Stock Options The Company will hold its Annual General Meeting on August 14th in Calgary, Alberta. More details will be included in the circular, which will be mailed in July to shareholders of record. The Company announces that it has granted 100,000 stock options to Ellen Briant, the Company’s CFO. The stock options to purchase common shares of the Company are exercisable at $0.32 per common share for a term of 5 years and vest immediately. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
|
For further information please contact:
George Adams, CEO
Phone: (519) 803-6047
Email: gadams@ventripoint.ca
| ||
